Acelrx Pharmaceuticals Inc Foglalás / Részvény
Mi az Acelrx Pharmaceuticals Inc Foglalás / Részvény?
A Foglalás / Részvény az Acelrx Pharmaceuticals Inc - 0.08
Mi a Foglalás / Részvény meghatározása?
Az egy részvényre jutó könyv szerinti érték egy vállalat eszköze, mínusz kötelezettségek, osztva a fennálló részvények számával.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Foglalás / Részvény a Health Care szektor a NASDAQ-on cégekben a Acelrx Pharmaceuticals Inc -hoz képest
Mit csinál Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
foglalás / részvény -hoz hasonló cégek Acelrx Pharmaceuticals Inc
- Stampede Capital nak Foglalás / Részvény 0.08 van
- Twintek Investment nak Foglalás / Részvény 0.08 van
- Alloy Resources nak Foglalás / Részvény 0.08 van
- New Oroperu Resources nak Foglalás / Részvény 0.08 van
- Spartan Acquisition nak Foglalás / Részvény 0.08 van
- Labrador Gold nak Foglalás / Részvény 0.08 van
- Acelrx Pharmaceuticals Inc nak Foglalás / Részvény 0.08 van
- American Rare Earths nak Foglalás / Részvény 0.08 van
- 5G Networks nak Foglalás / Részvény 0.08 van
- Visioneering Technologies nak Foglalás / Részvény 0.08 van
- Loco Hong Kong nak Foglalás / Részvény 0.08 van
- Four Arrows Capital nak Foglalás / Részvény 0.08 van
- Sintana nak Foglalás / Részvény 0.08 van